ASCO Annual Meeting: Lung Cancer

Articles

Patients with chemotherapy-naïve, locally advanced, or metastatic non-small cell lung cancer who were treated with tiragolumab plus an anti-PD-L1 agent showed better efficacy versus single-agent checkpoint inhibitor therapy alone.

Phase 2 CITYSCAPE Trial Shows Promise for Tiragolumab in NSCLC

Fam-trastuzumab deruxtecan-nxki (Enhertu) showed favorable clinical activity with a high objective response rate and durable responses in patients with HER2-mutated non-small cell lung cancer.

Antibody Drug Conjugate Shows Favorable Clinical Activity in Phase 2 DESTINY-Lung01 Study

The study demonstrated modest survival benefits in patients with extensive-stage small cell lung cancer who received the combination of pembrolizumab and etoposide plus platinum (EP).

Phase 3 KEYNOTE-604 Trial Shows Promise for Pembrolizumab and EP in Patients ES-SCLC

The addition of durvalumab to standard chemotherapy continued to demonstrate an improvement in overall survival for patients with treatment-naïve extensive-stage small cell lung cancer.

Phase 3 CASPIAN Study Supports Durvalumab Regimen in ES-SCLC

Combining tislelizumab with chemotherapy improved progression-free survival compared with chemotherapy alone as a frontline treatment in Chinese patients with advanced squamous non-small cell lung cancer.

Tislelizumab Plus Chemotherapy Improves PFS in Chinese Patients with NSCLC

Tepotinib demonstrated durable clinical activity in patients with locally advanced or metastatic non-small cell lung cancer who harbor a MET exon 14 skipping mutation identified through liquid or tissue biopsy.

Phase 2 VISION Trial Shows Promise for Tepotinib in NSCLC

The updated findings indicated that alectinib demonstrated a clinically meaningful improvement in overall survival compared with crizotinib in patients with ALK-positive non-small cell lung cancer.

Updated Phase 3 ALEX Trial Data Finds Alectinib Maintains Significant Benefit in ALK+ NSCLC

Overall survival (OS) benefit derived from frontline treatment with nivolumab plus ipilimumab combined with 2 cycles of platinum-doublet chemotherapy in patients with metastatic or recurrent non-small cell lung cancer was further improved after at least 12 months of follow-up.

Frontline Nivolumab/Ipilimumab with Limited Chemo Derives OS Benefit in NSCLC

Frontline treatment with nivolumab plus ipilimumab induced durable and long-term efficacy, compared with chemotherapy, in patients with advanced non-small cell lung cancer, regardless of PD-L1 expression.

Nivolumab/Ipilimumab Combo Yields Durable Efficacy in Advanced NSCLC

Phase III data, presented at the 2020 ASCO Virtual Scientific Program, showed that treatment with osimertinib dramatically improved disease-free survival compared to placebo for patients with EGFR-mutated advanced NSCLC.

ASCO Annual Meeting: Lung Cancer | Conference